Bayer Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Healthcare Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Aktiengeselischaft

Other

Bayer Pharmaceuticals Corporation

Bayer Aktiengeselechaft

Bayer Aktlengesellschaft

Elisabeth Perzborn

Klaus Dembowsky

Karl-Heinz Schlemmer

Friedel Seuter

Alexander Straub

Erwin Bischoff

Ulrich Rosentreter

Johannes-Peter Stasch

Thomas Lampe

Ulrich Niewohner

Mazen Es-Sayed

Helmut Haning

Achim Feurer

Horst Boshagen

Folker Lieb

Elke Stahl

Thomas Schenke

Frank Wunder

Gunter Schmidt

Ulrich E Muller

Susanne Röhrig

Thomas Jaetsch

Matthias Schramm

Raimund Kast

Dieter Lang

Dieter Arlt

Joachim Hutter

Jörg Keldenich

Josef Pernerstorfer

Gerhard Franckowiak

Rainer Gross

Hans-Georg Lerchen

Markus Heil

Paul Naab

Bodo Junge

Martin Bechem

Walter Hübsch

Andrea Vaupel

Joerg Keldenich

Andreas Knorr

Siegfried Goldmann

Horst Meyer

Klaus Sasse

Klaus Schaller

Siegfried Raddatz

Hans-Joachim Kabbe

Christoph Gerdes

Walter Puls

Wolfgang Hartwig

Mark Jean Gnoth

Mario Jeske

Volker-Bernd Fiedler

Jens Pohlmann

Cristina Alonso-Alija

Ulrich Niew&ouml;hner

Hermann Oediger

Dietmar Flubacher

Franz-Peter Hoever

Marc Nowakowski

Joachim H&uuml;tter

Peter Serno

Stefan Weigand

Hilary P Francis

Joseph Pernerstorfer

Susanne Rohrig

Peter Norman

Chantal F&uuml;rstner

Ulrich Niewöhner

Romanis Fruchtmann

Christian Kohlsdorfer

Michael Kayser

Klaus Mohrs

Nigel J Cuthbert

Mithat Mardin

Hans-Georg Dellweg

Maria Niewöhner, Legal Representative

Ursula Krenz

Klaus Schlossmann

Gunther Thomas

Thomas Krahn

Marcus Bauser

Oswald Lockhoff

J&ouml;rg Keldenich

Friedrich Hoffmeister

Rolf Henning

Peter Kurka

Thomas Krämer

Wolf-Dieter Busse

Gunter Thomas

Reiner Muller-Peddinghaus

Trevor S Abram

Graham Sturton

Bernhard Pelster

Metin Akbaba

Gerd Reinhardt

Fred R Heiker

Maria Niewöhner

Sabine Arndt

Joachim Ippen

Christian R Thomas

The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.

Substituted oxazolidinones and their use in the field of blood coagulation

The present application relates to prodrug derivatives of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.

Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders

Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders

The present application relates to prodrug derivatives of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-morpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.

The present application relates to novel 2-aminoethoxyacetic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.

2-aminoethoxyacetic acid derivatives and their use

The invention relates to combinations of A) oxazolidinones of formula (I) and B) other active ingredients, to a method for producing said combinations and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases. 

Substituted oxazolidinones for combinational therapy

The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.

2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors

The application claims a compound of the formula  The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.

The present invention relates to the use of compounds of the formula (I) and to their salts and stereoisomers, for the preparation of medicaments for the treatment of cardiovascular disorders.

Dicarboxylic acid derivatives with pharmaceutical properties

The invention relates to the field of blood coagulation, more particularly, to novel compounds of general formula (I), to a method for producing the compounds and to their use as active ingredients in medicaments for the prevention and/or the treatment of diseases.

Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolines and their use as anticoagulant and antithrombotics

Growing community of inventors

Wuppertal, Germany

Elisabeth Perzborn